Atopic Dermatitis

New research on updadacitinib’s use for atopic dermatitis patients suggests the drug may be effective for hand eczema.

A recent study on allergies to methylchloroisothiazolinone or methylisothiazolinone, with findings suggesting that European regulations may have diminished sensitivity rates.

This segment of Raj Chovatiya’s interview with HCPLive, a discussion was conducted regarding facts about abrocitinib for atopic dermatitis treatment.

During an HCPLive interview on his presentation at Winter Clinical, Raj Chovatiya discussed the use of abrocitinib on atopic dermatitis patients.

An overview of some of the biggest articles in the dermatology field covered this week, including new breakthroughs in research.

A recent study demonstrated that a combined treatment of topical corticosteroids and lebrikizumab led to reduced atopic dermatitis severity compared to the non-lebrikizumab group.

A new study from Denmark explored the ineffectiveness associated with dupilumab in certain regions of the body after long-term examination.

A recent study examined the increased rates of eczema on the hands of health workers more during the COVID-19 outbreak.

Allergic contact dermatitis burden many people, but it is important for patients to know why and how they may limit their risk.

An interview segment with Peter Young featuring a description of the response to the research into personal care product allergens.

A segment of an interview with Peter Young in which he describes his original interest in the subject of skincare product allergens.

A new study explored the topic of predictive biomarkers of clinical improvement of EASI scores for atopic dermatitis patients being given dupilumab.

Dr. Raj Chovatiya discusses how recent approvals will influence the way in which he and other dermatologists will manage atopic dermatitis going forward.

An interview with Karan Lal, DO, regarding skincare product allergens, misdiagnosis of allergic contact dermatitis, and more.

Researchers have developed an automated hair loss measurement system for alopecia patients to track hair loss.

Research indicates the long-term benefits of sustained use of two developed online interventions for younger patients diagnosed with eczema.

Recent research has identified two groups as high risk for developing asthma, with one noted as having early eczema and the other not having the skin condition.

By combining specific severity-associated serum biomarkers, investigators were able to predict atopic dermatitis severity in children.

Though avoidance of common food allergens is a popular practice among patients with atopic dermatitis, clinical trial evidence doesn't support its benefit compared to its risks.

Mixed emollients were effective in preventing infant atopic dermatitis development compared to standard care.

Research suggested no significant relationship between peanut sensitivity and AD severity as measured by two scores, although the study was acknowledged to have a smaller population due to pandemic restrictions.

Both direct and indirect costs were higher in patients with mild-to-moderate and severe atopic dermatitis compared to the control group.

A Q&A interview with Dr. Simpson regarding the recent INTEGUMENT clinical trial results regarding roflumilast for atopic dermatitis.

New long-term phase 3 data show adults and adolescents both improved measures of quality of life when treated with either of 2 doses of ruxolitinib cream.

Findings from the ongoing LIBERTY AD OLE trial show the sustained long-term effect of the biologic therapy for eczema.

New data show adults receiving the biologic for eczema may see improvements in sleep disturbance within 4 weeks.

Post hoc analysis data from JADE REGIMEN show continuous and reduced-dose regimens provided similar efficacy and safety outcomes in the 2 age groups.

Phase 3 data suggest children aged <6 months to 5 years old have benefit in itch relief and skin clearance as soon as 1 week into systemic therapy regimens.

New data from ECZTRA 1 and 2 show patients unable to achieve complete skin clearance nonetheless benefitted in at least 1 component of disease improvement.

Phase 3 trial data from the INTEGUMENT-1 study yielded positive results for roflumilast cream on atopic dermatitis patients ages 6 and up.